Theresa Guo1, Eleni Rettig1, Carole Fakhry2. 1. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. 2. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA; Milton J. Dance Jr. Head and Neck Center, Baltimore, MD 21204, USA; Bloomberg School of Public Health, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. Electronic address: cfakhry@jhmi.edu.
Abstract
OBJECTIVES: Human papillomavirus (HPV)-positive tumor status is associated with improved prognosis after disease recurrence in oropharyngeal squamous cell carcinoma (OPSCC). In this study the potential role of survival bias in the relationship between HPV tumor status and the timing of recurrence was evaluated, given conflicting evidence in the literature. MATERIALS & METHODS: A secondary analysis was performed on a previously published retrospective two institution study of recurrent OPSCC with known HPV tumor status. Patients were categorized as "early" (surviving <24 months) or "late" survivors (⩾24 months). Timing of first recurrence and overall survival were analyzed using Kaplan-Meier and cox proportional hazard methods. Two-sided p-values <0.05 were considered significant. RESULTS: In total 101 patients met criteria including 81 late and 20 early survivors. HPV-positive tumor status was associated with longer time to recurrence in late survivors (median 21.8 vs. 13.8 months, p=0.028). Late survivors had later recurrences in HPV-positive (p<0.001) and HPV-negative patients (p=0.0096), as well as in both locoregional (p<0.0001) and distant metastatic recurrence (p<0.0001). In multivariate analysis, both HPV-positive tumor status (adjusted HR [aHR] 0.48, p=0.006) and survival beyond 24 months (aHR 0.21, p<0.001) were associated with later recurrence. When stratified, HPV tumor status was only associated with later recurrence in late survivors (aHR 0.47, p=0.015). CONCLUSIONS: Late survivorship was associated with late recurrence for both HPV-positive and HPV-negative patients. Stratification by survival illustrates how survival bias links late survivorship with late recurrences and contributes to our understanding of the impact of HPV tumor status on the timing of recurrence.
OBJECTIVES:Human papillomavirus (HPV)-positive tumor status is associated with improved prognosis after disease recurrence in oropharyngeal squamous cell carcinoma (OPSCC). In this study the potential role of survival bias in the relationship between HPV tumor status and the timing of recurrence was evaluated, given conflicting evidence in the literature. MATERIALS & METHODS: A secondary analysis was performed on a previously published retrospective two institution study of recurrent OPSCC with known HPV tumor status. Patients were categorized as "early" (surviving <24 months) or "late" survivors (⩾24 months). Timing of first recurrence and overall survival were analyzed using Kaplan-Meier and cox proportional hazard methods. Two-sided p-values <0.05 were considered significant. RESULTS: In total 101 patients met criteria including 81 late and 20 early survivors. HPV-positive tumor status was associated with longer time to recurrence in late survivors (median 21.8 vs. 13.8 months, p=0.028). Late survivors had later recurrences in HPV-positive (p<0.001) and HPV-negative patients (p=0.0096), as well as in both locoregional (p<0.0001) and distant metastatic recurrence (p<0.0001). In multivariate analysis, both HPV-positive tumor status (adjusted HR [aHR] 0.48, p=0.006) and survival beyond 24 months (aHR 0.21, p<0.001) were associated with later recurrence. When stratified, HPV tumor status was only associated with later recurrence in late survivors (aHR 0.47, p=0.015). CONCLUSIONS: Late survivorship was associated with late recurrence for both HPV-positive and HPV-negative patients. Stratification by survival illustrates how survival bias links late survivorship with late recurrences and contributes to our understanding of the impact of HPV tumor status on the timing of recurrence.
Authors: Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison Journal: J Clin Oncol Date: 2014-06-23 Impact factor: 44.544
Authors: Brian O'Sullivan; David L Adelstein; Shao Hui Huang; Shlomo A Koyfman; Wade Thorstad; Andrew J Hope; James S Lewis; Brian Nussenbaum Journal: J Clin Oncol Date: 2015-03-30 Impact factor: 44.544
Authors: Shao Hui Huang; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew Hope; Christine Massey; John N Waldron; John Kim; Andrew J Bayley; Bernard Cummings; B C John Cho; Jolie Ringash; Laura A Dawson; Lillian L Siu; Eric Chen; Jonathan Irish; Patrick Gullane; Angela Hui; Fei-Fei Liu; Xiaowei Shen; Wei Xu; Brian O'Sullivan Journal: Oral Oncol Date: 2012-08-20 Impact factor: 5.337
Authors: Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Justin A Bishop; Takenori Ogawa; Xiaofei Chang; Peter B Illei; Edward Gabrielson; Sara I Pai; William H Westra Journal: Am J Surg Pathol Date: 2012-01 Impact factor: 6.394
Authors: P Sinha; W T Thorstad; B Nussenbaum; B H Haughey; D R Adkins; D Kallogjeri; J S Lewis Journal: Oral Oncol Date: 2013-11-06 Impact factor: 5.337
Authors: Jeffrey Vainshtein; Jonathan B McHugh; Matthew E Spector; Heather M Walline; Christine M Komarck; Matthew H Stenmark; Mark E Prince; Francis P Worden; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Thomas Carey; Avraham Eisbruch Journal: Head Neck Date: 2014-04-15 Impact factor: 3.147
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Carole Fakhry; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni Rettig; Linda X Yin; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; Jeremy D Richmon; David W Eisele; Gypsyamber D'Souza Journal: Cancer Date: 2017-02-27 Impact factor: 6.860
Authors: Linda X Yin; Gypsyamber D'Souza; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni M Rettig; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; David W Eisele; Carole Fakhry Journal: Laryngoscope Date: 2018-03-14 Impact factor: 3.325
Authors: Marjolein Je Greuter; Charlotte S Schouten; Jonas A Castelijns; Pim de Graaf; Emile Fi Comans; Otto S Hoekstra; Remco de Bree; Veerle Mh Coupé Journal: BMC Cancer Date: 2017-04-11 Impact factor: 4.430
Authors: Christian Grønhøj Larsen; David H Jensen; Amanda-Louise Fenger Carlander; Katalin Kiss; Luise Andersen; Caroline Holkmann Olsen; Elo Andersen; Emilie Garnæs; Finn Cilius; Lena Specht; Christian von Buchwald Journal: Oncotarget Date: 2016-11-01
Authors: Malin Wendt; Lalle Hammarstedt-Nordenvall; Mark Zupancic; Signe Friesland; David Landin; Eva Munck-Wikland; Tina Dalianis; Anders Näsman; Linda Marklund Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639
Authors: Madhava R Kanakamedala; Shankar P G Giri; Robert D Hamilton; Eldrin Bhanat; Srinivasan Vijayakumar Journal: Head Neck Date: 2018-01-31 Impact factor: 3.147